Visterra, founded in 2008, based on technologies from the Sasisekharan Lab. The Hierotope™ platform identifies regions on an antigen critical to the molecule’s structure and function, and designs therapeutics to target that epitope.
Visterra’s completed a Series C financing totaling $46.7 million. Since 2008, Visterra had raised $122.1 million in venture funding. Visterra has been acquired by Otsuka Pharmaceuticals
Visterra’s Hierotope™ Platform utilizes proprietary technology, drug design and engineering and know-how deployed through a distinctive drug discovery and development process.
Image courtesy of Visterra
